Related Experiment Videos
Dysfunction of the hypothalamic-pituitary system in mitochondrial encephalomyopathies
N Ohkoshi1, A Ishii, N Shiraiwa
1Department of Neurology, Institute of Clinical Medicine, University of Tsukuba, Japan.
Journal of Medicine
|August 15, 1998
Summary
Mitochondrial encephalomyopathies like MELAS and MERRF often cause hypothalamic-pituitary dysfunction, affecting hormones crucial for growth and development. Patients with CPEO showed no such endocrine impairment.
Area of Science:
- Endocrinology
- Neurology
- Genetics
Background:
- Mitochondrial myopathies, including MELAS, MERRF, and CPEO, are rare genetic disorders affecting cellular energy production.
- Endocrine dysfunction is a potential complication, but its prevalence across different mitochondrial disease subtypes is not well-defined.
Observation:
- Investigated endocrine function in patients diagnosed with MELAS, MERRF, and CPEO.
- Assessed hypothalamic-pituitary axis function through hormone level measurements and stimulation tests.
Findings:
- Significant hypothalamic-pituitary dysfunction was observed in patients with MELAS and MERRF.
- One MELAS patient exhibited dwarfism and impaired development due to decreased growth hormone, LH, and FSH.
- A MERRF patient presented with emaciation and low adrenocorticotropin levels.
- A transitional MELAS/MERRF patient displayed blunted LH and FSH responses to GnRH stimulation.
Implications:
- Mitochondrial encephalomyopathies, particularly MELAS and MERRF, are strongly associated with hypothalamic-pituitary dysfunction.
- Early endocrine screening is recommended for patients with MELAS or MERRF to manage potential hormonal deficiencies.
- Understanding these endocrine complications is vital for comprehensive patient care and improving clinical outcomes.